Kewaunee Scientific Corporation Reports Strong Fiscal Year Results
Kewaunee Scientific Corporation (NASDAQ: KEQU) has recently shared its financial outcomes for the fourth quarter and its entire fiscal year. The company experienced substantial growth in sales and earnings, showcasing its effective strategies and performance improvements.
Financial Overview of Fiscal Year 2025
For the fourth quarter of 2025, Kewaunee Scientific reported sales of $77,148,000, marking a remarkable increase of 36.1% compared to $56,702,000 in the previous year. Pre-tax earnings saw a significant rise to $7,149,000 from just $1,347,000 last year. However, net earnings decreased to $4,850,000 from $11,026,000, while diluted earnings per share shifted from $3.71 to $1.63.
Key Insights from Fiscal Year Performance
The order backlog stood at $214.6 million at the end of the fiscal year, reflecting a slight decrease from $221.6 million at the start of the year but a considerable increase from $155.6 million a year ago. This solid order backlog demonstrates Kewaunee's strength in the market.
Adjustments and Non-Recurring Transactions
Management indicated that during the prior year's fourth quarter, two notable non-recurring transactions took place, influencing the reported earnings and EBITDA figures. The first involved successfully annuitizing a long-standing pension obligation, which incurred a one-time non-cash expense. The second transaction involved a partial release of the valuation allowance, leading to an additional tax benefit.
Operational Highlights
During 2025, acquisition and integration costs related to Nu Aire, Inc., which Kewaunee acquired on November 1, 2024, reduced pre-tax earnings by $1,258,000 and adjusted EBITDA by $650,000. After these adjustments, the company's pre-tax earnings for the current quarter were at $8,407,000, compared to the prior year’s $5,366,000, reflecting a striking increase of 56.7%.
Segment Performance
Domestic Segment: The domestic sales surged to $55,490,000 for the quarter, showcasing a 54.7% uplift from $35,859,000 in the previous year. This segment's net earnings rose to $5,099,000, showcasing robust performance driven primarily by increased manufacturing activities and incorporation of Nu Aire's results.
International Segment: International sales also saw a boost, reaching $21,658,000, a 3.9% increment compared to $20,843,000 last year. The net earnings for this segment rose to $1,607,000 against $1,138,000 in the prior year.
Corporate Segment Performance
The corporate segment reported a net loss of $1,856,000, down from a profit of $6,478,000 in the previous year. This loss was significantly impacted by the costs related to Nu Aire's acquisition and Sarbanes-Oxley compliance preparations. Excluding these costs, the adjusted corporate segment EBITDA loss was $1,375,000, demonstrating a considerable impact of recent events on overall performance.
Fiscal Year 2025 Results Summary
For the entirety of fiscal year 2025, Kewaunee's sales totaled $240,472,000, a commendable 18.0% rise from $203,755,000 the prior year. Pre-tax earnings grew to $14,785,000, compared to $13,119,000 in the previous period, while net earnings for this fiscal cycle reached $11,405,000 against $18,753,000 last year. Despite challenges, the diluted earnings per share came in at $3.83, down from $6.38.
Segregated Results
The domestic segment total revenue amounted to $179,398,000, with net earnings of $15,370,000 compared to $11,808,000 the prior year. Conversely, international sales saw a slight downturn to $61,074,000, down 8.2% from last year, reflecting challenges faced in the global market.
Strategic Growth and Market Position
The acquisition of Nu Aire has marked a significant step forward for Kewaunee, expanding its product offerings in the laboratory and biosafety solutions space which can help drive cross-selling opportunities in the near future. The focus on enhancing relationships with channel partners and strategic growth initiatives positions Kewaunee for further success moving forward.
Consolidated Capital Management and Financial Health
As part of its financial health monitoring, Kewaunee announced a decline in cash on hand to $17,164,000 from $25,938,000 the previous year, largely due to the acquisition costs incurred. However, the total working capital increased to $64,651,000 from $56,037,000, indicating growing operational efficiency.
Overall, Kewaunee Scientific Corporation's results for fiscal year 2025 highlight significant achievements amidst industry challenges, demonstrating resilience and strategic foresight for continued growth and profitability.
Frequently Asked Questions
What were Kewaunee Scientific's financial results for Q4 and FY 2025?
Kewaunee Scientific recorded a 36.1% increase in Q4 sales, totaling $77,148,000. For FY 2025, total sales were $240,472,000, marking an 18.0% increase.
Who is Kewaunee Scientific Corporation?
Kewaunee Scientific Corporation is a global leader in designing and manufacturing laboratory, healthcare, and technical furniture products, founded in 1906.
What was the impact of the Nu Aire acquisition on Kewaunee's finances?
The acquisition of Nu Aire significantly impacted Kewaunee's financials by increasing operational costs but enhancing its product offerings in the laboratory equipment sector.
How did Kewaunee perform in international markets in FY 2025?
The international segment revenue decreased by 8.2%, totaling $61,074,000, primarily due to global market challenges.
What are Kewaunee's future growth strategies?
Kewaunee aims to grow organically and through acquisitions while strengthening its relationships with dealer and distribution partners.
